Since publication of the last full practice guideline and guideline watch on schizophrenia, there have been a multitude of studies on new pharmacological and nonpharmacological treatments for schizophrenia.
This study looked at how clients of a coordinated specialty care (CSC) program for first-episode psychosis perceived how they changed while attending the program, what the most important changes were, and what mechanisms they believed helped bring about these changes.
Researchers determined the prevalence of neuropsychiatric systemic lupus erythematosus in patients with psychosis with positive antinuclear antibodies.
ALKS 3831 is composed of samidorphan, a mu-opioid receptor antagonist, which is co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.
This study investigates whether contralateral delay activity occurs early in schizophrenia, possibly indicating that visual short-term memory deficits are a core feature of the disorder.
Data on thyroid hormone levels during the course of schizophrenia disorder are sparse. This study assessed the rate of thyroid hormone disorders in outpatients before and after a diagnosis of schizophrenia.
Short- to intermediate-term exposure to atypical antipsychotic medications may dysregulate adaptive immune responses, increasing susceptibility to respiratory infections like COVID-19.
Researchers conducted a systematic review and meta-analysis to assess the incidence and predictors of psychosis relapse in individuals receiving treatment with antipsychotic agents.
